Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

• Main Authors: Saei, A, Palafox, M, Benoukraf, T, Kumari, N, Jaynes, P.W, Iyengar, P.V, Muñoz?Couselo, E, Nuciforo, P, Cortés, J, Nötzel, C, Kumarakulasinghe, N.B, Richard, J.L.C, Isa, Z.F.B.A, Pang, B, Guzman, M, Siqin, Z, Yang, H, Tam, W.L, Serra, V, Eichhorn, P.J.A
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: Rockefeller University Press 2020
• Subjects: B Raf kinase; F box/WD repeat containing protein 7; FBXW7 protein, human; glycine; rigosertib; sulfone; ubiquitin thiolesterase; USP28 protein, human; vemurafenib; analogs and derivatives; animal; apoptosis; deficiency; down regulation; drug effect; drug resistance; gene deletion; HEK293 cell line; human; MAPK signaling; melanoma; metabolism; mouse; pathology; prognosis; protein degradation; protein stability; tumor cell line; Animals; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Gene Deletion; Glycine; HEK293 Cells; Humans; MAP Kinase Signaling System; Melanoma; Mice; Prognosis; Protein Stability; Proteolysis; Proto-Oncogene Proteins B-raf; Sulfones; Ubiquitin Thiolesterase; Vemurafenib
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/175109
• Institution: National University of Singapore

10.1084/jem.20171960